Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB Pharmaceuticals Inc. received an updated ownership report from RA Capital-affiliated investors. As of December 31, 2025, RA Capital Healthcare Fund, L.P. directly holds 2,208,604 shares of LB Pharmaceuticals common stock, representing 8.7% of the outstanding shares, based on 25,299,102 shares reported outstanding as of November 6, 2025.
RA Capital Management, L.P. acts as investment adviser to the fund, and Peter Kolchinsky and Rajeev Shah are controlling persons of the general partner entities. The filers state the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals and disclaim group status and beneficial ownership beyond what is required for Section 13(d) reporting.
Deep Track Capital and affiliates updated their ownership filing for LB Pharmaceuticals Inc. after participating in a private placement. Following the transaction, Deep Track Capital, LP and David Kroin report beneficial ownership of 3,352,804 shares of common stock, representing 11.7% of the company.
The issuer sold 3,306,571 common shares and pre-funded warrants to purchase up to 1,417,107 additional shares in the private placement. Deep Track Biotechnology Master Fund, Ltd holds 2,686,138 shares, or 9.4% of the class, and Deep Track Special Opportunities Fund, LP holds 666,666 shares, or 2.3%. The pre-funded warrants have a $0.0001 exercise price and are subject to a 9.99% beneficial ownership cap, so the reporting persons currently disclaim beneficial ownership of the underlying warrant shares. LB Pharmaceuticals agreed to register the resale of the purchased shares and warrant shares on a Form S-1 and to keep that registration effective under specified conditions.
LB Pharmaceuticals Inc. reported insider purchases of pre-funded warrants by Deep Track-affiliated funds. On February 6, 2026, Deep Track Biotechnology Master Fund, Ltd. acquired 378,444 pre-funded warrants, and Deep Track Special Opportunities Fund, LP acquired 93,925 pre-funded warrants, each at $21.1699 per warrant.
The pre-funded warrants are exercisable immediately at an exercise price of $0.0001 per share of common stock and do not expire. Their terms cap beneficial ownership at 9.99% of LB Pharmaceuticals’ outstanding common stock, preventing exercises that would put the holder and its affiliates above that threshold. Deep Track Capital, LP and David Kroin are reporting persons and state they may be deemed beneficial owners only to the extent of their pecuniary interests.
LB Pharmaceuticals Inc entered into a private placement financing, agreeing to sell 3,306,571 common shares and pre-funded warrants for up to 1,417,107 additional shares at prices around $21.17 per share, for estimated gross proceeds of about $100 million.
The company plans to use the net proceeds mainly to fund a Phase 2 trial of LB-102 as an adjunctive treatment for major depressive disorder, as well as for working capital and general corporate purposes. The multi-center, six-week trial is expected to enroll about 380 patients across roughly 50 sites in the U.S. and Europe.
LB Pharmaceuticals Inc. disclosed that BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in the company’s common stock. As of December 31, 2025, BlackRock reported beneficial ownership of 1,277,776 shares, representing 5.1% of LB Pharmaceuticals’ outstanding common stock.
BlackRock reported sole power to vote 1,262,836 shares and sole power to dispose of 1,277,776 shares, with no shared voting or dispositive power. The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals.
BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 961,158 shares, representing 3.8 % of the outstanding common stock. It has sole power to vote 863,342 shares and sole power to dispose of 961,158 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals. Various persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 1,611,482 shares, representing 6.3% of the company’s outstanding common stock as of the event date.
JPMorgan has sole voting power over 1,471,295 shares and sole dispositive power over 1,611,482 shares, with no shared voting or dispositive power. The filing is certified as being made in the ordinary course of business and states that the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals.
LB Pharmaceuticals reported that its chief commercial officer received an employee stock option grant covering 195,000 shares of common stock. The option, dated 12/10/2025, has an exercise price of $21.36 per share and expires on 12/09/2035.
One fourth of the shares vest on 11/10/2026, with the remaining shares vesting in 36 equal monthly installments on the last calendar day of each month starting 12/31/2026, subject to the officer’s continuous service. Following this grant, the officer beneficially owns 195,000 stock options, held directly.
LB Pharmaceuticals Inc. (LBRX) reported that its Chief Commercial Officer, listed as an officer of the company, filed an initial Form 3 statement of beneficial ownership. The filing states that, as of the reported event date, the officer has no securities beneficially owned in LB Pharmaceuticals. This establishes that the executive currently holds no direct or indirect ownership in the company’s securities under the relevant reporting rules.
LB Pharmaceuticals (LBRX) amended its headquarters lease to add 4,634 rentable square feet on the 10th floor at One Penn Plaza, New York. The underlying lease term remains scheduled to expire on March 31, 2032.
The landlord shall endeavor to deliver the Expansion Premises on or prior to July 1, 2026. From the Expansion Premises Commencement Date, fixed rent for the added space will be $430,962 per year for the first three years, increasing to $477,302 per year on the third anniversary. The parties agreed to a fixed rent abatement for the first 150 days after commencement, as set forth in the amendment.